The Complete Haematology Panel for Enhanced Athletes

Most bloodwork guides for enhanced athletes stop at two numbers: haemoglobin and haematocrit. If those look fine, you move on. If haematocrit crosses 54%, you book a phlebotomy. That is not good enough.

Your complete blood count (CBC) contains over a dozen markers across three cell lineages: red cells, white cells, and platelets. Each one tells you something different about how your body is responding to the compounds you are running. Red cell indices reveal whether your bone marrow is keeping up with the erythropoietic demand or running out of iron. The white cell differential shows whether your immune system is being pushed by androgens, infection, or both. Platelet markers flag thrombotic risk that haematocrit alone cannot capture.

This guide breaks down every component of the haematology panel in the context of PED use. If you have already read the basics of bloodwork for bodybuilders or our deep dive on haemoglobin and haematocrit, this is the next level.

Why the CBC matters beyond haemoglobin and haematocrit

A standard CBC measures three cell lineages produced by your bone marrow:

• Red blood cells (erythrocytes): oxygen transport. AAS stimulate this lineage aggressively.
• White blood cells (leukocytes): immune defence. Androgens shift the differential in predictable ways.
• Platelets (thrombocytes): clotting. Androgens increase both platelet count and platelet reactivity.

When you run AAS, all three lineages are affected simultaneously. Monitoring only haemoglobin and haematocrit is like checking your oil but ignoring the coolant and brake fluid. The full CBC gives you the complete picture of how your bone marrow is handling the pharmacological load.

The red blood cell panel

Haemoglobin, haematocrit, and RBC count

These three markers move together on cycle, but they measure different things:

• Haemoglobin (Hb): the oxygen-carrying protein inside each red cell, measured in g/L.
• Haematocrit (Hct): the percentage of your blood volume occupied by red cells.
• RBC count: the absolute number of red blood cells per litre of blood.

On AAS, haematocrit typically rises faster than haemoglobin. This is why your MCHC (mean corpuscular haemoglobin concentration) often drops on cycle: each red cell is slightly less haemoglobin-dense because production is outpacing haemoglobin synthesis (Alen, 1985). That pattern, Hct up, MCHC down, MCV stable, is the fingerprint of AAS-driven erythropoiesis and distinguishes it from dehydration (where Hct rises but RBC count stays the same).

In a controlled dose-escalation trial, testosterone enanthate at doses from 25 to 600 mg/week produced linear, dose-dependent increases in both haemoglobin and haematocrit, with significantly greater increases in older men at every dose (Coviello et al., 2008). At supraphysiological doses, expect haematocrit to climb 5-10 percentage points above baseline over 8-12 weeks.

Red cell indices: MCV, MCH, MCHC, and RDW

These four markers tell you about the quality of red cell production, not just the quantity.

• MCV (mean corpuscular volume): the average size of each red cell. On AAS, MCV typically stays stable. A dropping MCV during a cycle signals iron depletion from accelerated erythropoiesis. A rising MCV suggests B12 or folate deficiency.
• MCH (mean corpuscular haemoglobin): the average haemoglobin per cell. Follows MCV trends.
• MCHC: haemoglobin concentration per cell. Falls significantly on AAS as red cell volume expands faster than haemoglobin content.
• RDW (red cell distribution width): measures variation in red cell size. A rising RDW on cycle is an early warning sign. It means your bone marrow is producing two populations: older, iron-replete cells alongside newer, smaller, iron-depleted cells. This appears before ferritin drops to frankly deficient levels.

Reticulocytes: your bone marrow activity meter

Reticulocytes are immature red blood cells released from the bone marrow. Unlike haemoglobin and haematocrit, which reflect the cumulative mass of red cells in circulation, reticulocytes tell you what your bone marrow is doing right now.

In AAS users taking supraphysiological doses, serum EPO averaged 11.83 mIU/mL versus 6.60 mIU/mL in non-users (p = 0.03), with a strong positive correlation between EPO and reticulocyte percentage. Users with AAS-induced hypogonadism (ASIH) showed 75% higher EPO and 140% higher immature reticulocyte fractions compared to controls (Heiland et al., 2023).

This matters for timing. A rising reticulocyte count precedes a rising haematocrit by 7-14 days. If reticulocytes are climbing fast mid-cycle, your haematocrit is about to follow. After phlebotomy, reticulocytes peak around 7-10 days and normalise within two weeks, which is your window to confirm the bone marrow responded.

How AAS drive erythropoiesis

Testosterone stimulates red cell production through two concurrent mechanisms:

1. EPO stimulation. Testosterone increases renal erythropoietin production, establishing a new, higher EPO/haemoglobin set point that persists as long as testosterone remains elevated (Bachman et al., 2014).
2. Hepcidin suppression. Testosterone suppresses hepcidin (the iron gatekeeper hormone) in a dose-dependent fashion, unlocking more iron for red cell production (Bachman et al., 2010).

A third, recently discovered mechanism is direct extension of red cell lifespan. Hypogonadal men have shorter erythrocyte survival than eugonadal controls; testosterone treatment significantly extended red cell lifespan at 6 weeks, though this effect was transient and reversed by 18 weeks (McMartin et al., 2024). Even a transient lifespan extension contributes to haematocrit accumulation during the early weeks of a cycle, and the existing red cells still complete their normal lifespan (up to 120 days) before levels normalise after cessation.

One more thing worth knowing: these effects are driven by testosterone itself, not DHT. Co-administration of finasteride (substantially reducing DHT) did not attenuate erythropoiesis in a controlled study (Beggs et al., 2014). Taking finasteride for hair protection will not protect you from rising haematocrit.

Compound-specific erythropoietic risk profiles

Not all AAS raise your red cell markers equally. Here is how the major compounds compare.

Testosterone: the baseline driver

All forms of exogenous testosterone (enanthate, cypionate, propionate, undecanoate) stimulate erythropoiesis through the EPO/hepcidin dual mechanism. The response is strictly dose-dependent: at 125 mg/week (standard TRT), expect haematocrit to rise 2-5 percentage points. At 600 mg/week, the increase is substantially larger and faster. Injectable formulations carry higher erythrocytosis rates (up to 66.7% in some studies) compared to transdermal preparations (Liu et al., 2025).

Boldenone: the worst offender

Boldenone undecylenate (Equipoise) has a reputation in the bodybuilding community as disproportionately erythropoietic relative to its androgenic potency. This fits with its pharmacokinetic profile: the undecylenate ester gives it a long half-life, creating a sustained, compounding EPO stimulus that does not peak and trough the way shorter esters do. No head-to-head human RCT exists comparing boldenone to testosterone on CBC parameters, but the clinical observation is overwhelming: boldenone is the compound most likely to push you past the phlebotomy threshold.

Trenbolone and nandrolone

Trenbolone is a potent androgen receptor agonist that does not aromatise to oestrogen. This creates a distinctive pattern: erythropoietic stimulation without the plasma volume expansion that oestrogen provides. The result in some users is a disproportionately high haematocrit relative to total blood volume, worsening viscosity.

Nandrolone decanoate has moderate erythropoietic effects and has been shown to potentiate exogenous EPO in renal patients, raising haematocrit from 24.4% to 32.9% with combined therapy versus EPO alone. In a bodybuilding context where athletes sometimes stack nandrolone with other erythropoietic compounds, this synergy matters.

Oxymetholone: the paradox

Oxymetholone (Anadrol) is the only AAS with an FDA approval for treating anaemia caused by deficient red cell production. Response rates in aplastic anaemia are 54.1% for non-severe cases and 13.5% for severe cases (Pengthina & Saelue, 2022). Yet at the supraphysiological doses bodybuilders use (50-150 mg/day), chronic use can exhaust haematopoietic stem cells. Its 17-alpha-alkylation also creates dose-dependent hepatotoxicity that limits duration of use.

Stanozolol: a different kind of risk

Stanozolol (Winstrol) does not strongly raise haematocrit via EPO stimulation. Its distinctive haematological fingerprint is on the coagulation axis: in animal models, it accelerates neutrophil precursor maturation in bone marrow (Inamdar Doddamani & Jayamma, 2012), and it enhances platelet aggregation through separate mechanisms. More on this in the platelets section below.

Peptides and growth hormone

MK-677 (ibutamoren) sustains GH pulse amplitude and raises IGF-1 from approximately 188 to 264 ng/mL. IGF-1 synergises with EPO at erythroid progenitor cells: adults with GH deficiency have red cell mass approximately 10% below predicted norms, and GH replacement increases red cell mass by about 183 mL over three months (Christ et al., 1997). MK-677 users rarely develop frank polycythemia, but may see mild haemoglobin and haematocrit rises over 6-12 months. The more pressing MK-677 concern for bloodwork is insulin resistance and HbA1c elevation.

Exogenous EPO (sometimes used alongside AAS in competitive bodybuilding) produces far more extreme erythrocytosis and is responsible for the most dangerous haematocrit readings seen in this population.

The white blood cell differential

What happens to WBC on cycle

Most guides do not mention white blood cells in the context of AAS use, but androgens are potent granulopoietic stimulants. In a controlled dose-escalation trial, testosterone at 300 mg/week raised absolute neutrophil counts by over 1,177 cells/uL (p < 0.001), with parallel increases in monocytes. Lymphocyte counts did not change (Gagliano-Juca et al., 2020).

The mechanism is myeloid progenitor skewing. Red cells, neutrophils, and monocytes all derive from a common myeloid progenitor, while lymphocytes do not. When testosterone drives the myeloid lineage harder, you get more of all three: more red cells, more neutrophils, more monocytes. This is why erythrocytosis and neutrophilia appear together on cycle.

Neutrophil-to-lymphocyte ratio shifts

The neutrophil-to-lymphocyte ratio (NLR) is increasingly used as a marker of systemic inflammation. Reference ranges for male athletes are around 1.36 (range 0.70-2.89) (Wang et al., 2025), significantly lower than the general population.

On cycle, the selective neutrophilia without lymphocyte changes pushes NLR upward. An on-cycle NLR of 2.5-4.0 driven by neutrophilia without lymphocytopenia is likely a pharmacological effect, not infection or systemic inflammation. But do not dismiss it entirely: in the TRAVERSE trial (5,204 men), testosterone-induced increases in neutrophils and monocytes were independently associated with venous thromboembolism risk, with an OR of 1.32 per standard deviation increase in neutrophils (Gagliano-Juca et al., 2025).

When elevated WBC is benign versus concerning

Differentiating AAS-driven neutrophilia from infectious leukocytosis:

• AAS-driven: neutrophils and monocytes up, lymphocytes stable, no fever, no band neutrophils (left shift) on the differential, no symptoms.
• Infection: all WBC lines may rise, band neutrophils present, fever, malaise, elevated CRP.
• Concerning regardless of cause: WBC persistently above 11.0 x10^9/L, immature granulocytes present, or basophils and eosinophils significantly elevated.

Platelets and thrombotic risk

Platelet count and MPV

Platelet count and mean platelet volume (MPV) are reported on every CBC but rarely discussed in AAS contexts. Androgens at supraphysiological doses enhance platelet activity through multiple molecular mechanisms: upregulation of thromboxane A2 receptor density, upregulation of P2Y12 receptor expression, and enhanced intracellular calcium signalling via the androgen receptor (Rosca et al., 2021).

An elevated MPV with a normal or low platelet count can indicate bone marrow stress or accelerated platelet turnover. Persistent platelet elevation above 450 x10^9/L warrants haematology review to rule out myeloproliferative disorders.

Stanozolol as a case study in platelet risk

Stanozolol's haematological profile is paradoxical. At therapeutic doses, it enhances tissue plasminogen activator (tPA) activity and was historically investigated as a treatment for venous thrombosis (Kluft et al., 1984). At supraphysiological doses, combined with its acceleration of granulopoiesis and the lipid and vascular damage from co-administered compounds, the net balance shifts toward thrombotic risk. In a pilot study of weight lifters, older AAS users required significantly lower collagen concentrations to achieve 50% platelet aggregation compared to younger users (1.47 vs 3.35 ug/mL, p = 0.01) (Ferenchick et al., 1992).

The combined thrombotic risk

The HAARLEM study (100 amateur athletes, median dose 901 mg/week, median cycle 13 weeks) documented D-dimer levels 1.3x higher during AAS use than at baseline, with prolonged clot lysis time and elevated procoagulant factors. Oral AAS users showed greater changes than injectable-only users. All coagulation parameters normalised within 3 months of cessation (Camilleri et al., 2023).

An athlete with haematocrit at 52%, WBC at 9.5 x10^9/L, enhanced platelet reactivity, and elevated D-dimer who then trains in heat without adequate hydration is stacking haemoconcentration on top of an already thrombogenic baseline. In polycythemia vera data, WBC at or above 8.5 x10^9/L carried a hazard ratio of 1.47 for thrombotic events (rising to 1.87 for WBC at or above 11 x10^9/L), and sustained haematocrit above 45% carried a hazard ratio of 1.61 (Tashi, 2022). These risks are additive.

Red flags: when your CBC needs urgent attention

NRBCs in peripheral blood

Nucleated red blood cells (NRBCs) are normally absent in healthy adults. Their appearance in your CBC reflects severe erythropoietic stress: the bone marrow is releasing immature cells that should still be maturing (Pikora et al., 2023). In an enhanced athlete, NRBCs at greater than 1/100 WBC should trigger immediate investigation, not a wait-and-see approach. This is most often seen with extreme AAS stacking, EPO use, or combined hypoxic stress.

Primary versus secondary polycythemia

If your haematocrit is persistently elevated, your doctor needs to distinguish between two very different conditions:

• Secondary polycythemia (what AAS cause): elevated or normal EPO, JAK2 V617F mutation negative. The bone marrow is responding to an external stimulus. Remove the stimulus, the problem resolves.
• Polycythemia vera (a blood cancer): low EPO, JAK2 V617F mutation positive in 95-98% of cases (Gangat et al., 2023). Requires haematology management.

A 2025 systematic review found that only 15.9% of studies on drug-induced erythrocytosis measured serum EPO and only 11.1% ordered JAK2 testing (Liu et al., 2025). If your haematocrit exceeds 54% and your doctor does not order these tests, ask for them.

The haematocrit threshold

The Endocrine Society guideline sets haematocrit above 54% as the threshold to halt testosterone therapy until levels normalise (Bhasin et al., 2018). But cardiovascular risk begins escalating well before that. Men with haematocrit at or above 52% on testosterone had significantly higher rates of major adverse cardiovascular events and venous thromboembolism (OR 1.35, 95% CI 1.13-1.61) compared to men without polycythemia (Ory et al., 2022).

A documented case shows what the extreme end looks like: a 49-year-old bodybuilder using multiple AAS presented with a left parietal ischaemic stroke with haemorrhagic conversion (Gerstmann syndrome), haemoglobin of 182 g/L, and haematocrit of 55.2% (Long et al., 2019).

Confounders that amplify haematological risk

Iron depletion from accelerated erythropoiesis

Testosterone suppresses hepcidin, unlocking iron for red cell production. When erythropoiesis is running at full throttle, ferritin drops even while haematocrit climbs. This is the iron paradox: low ferritin, high haematocrit, and newer red cells trending microcytic (falling MCV). Many athletes misinterpret low ferritin as "anaemia" and supplement iron aggressively, further fuelling the erythropoietic drive.

Phlebotomy makes this worse. Each 500 mL unit of blood removes 200-250 mg of iron. A study of 27 repeat blood donors on TRT found that 44% had persistently elevated haemoglobin at or above 180 g/L at subsequent donations (Chin-Yee et al., 2017). Chronic phlebotomy depletes iron stores, drops tissue pO2, and may paradoxically stimulate additional EPO production and reticulocyte rebound (Bond et al., 2024).

Sleep apnoea as a haematocrit amplifier

Obstructive sleep apnoea (OSA) causes nocturnal hypoxia that independently drives EPO production. In a retrospective cohort of 474 hypogonadal men on TRT, OSA was independently associated with polycythemia (OR 2.09, 95% CI 1.17-3.76) after adjusting for age, BMI, and testosterone levels (Lundy et al., 2020). A meta-analysis confirmed the effect is significant only in severe OSA (SMD 0.34, p < 0.01), not mild or moderate (Rha et al., 2022).

This is particularly relevant for off-season athletes running bulking protocols at high body weights. If your haematocrit is climbing faster than your dose and compound selection would predict, get screened for OSA. The STOP-Bang questionnaire takes two minutes.

Dehydration and pseudopolycythemia

Dehydration can raise haematocrit by 5-15% through haemoconcentration, which normalises completely with rehydration. A fasted, low-fluid morning draw after heavy training can falsely cross intervention thresholds. Standardise your draw conditions: mid-morning, well-hydrated, no intense training in the previous 12 hours.

How often to test: monitoring frequency by compound type

For complete monitoring timelines across all marker categories, see our blood test timing guide and PCT bloodwork guide.

Management protocols

Dose reduction: always first-line

Before reaching for a phlebotomy appointment, address the root cause. The Endocrine Society and AUA guidelines both recommend dose reduction as the primary intervention for AAS-induced erythrocytosis. Switching from intramuscular to subcutaneous or transdermal administration also reduces erythrocytosis rates significantly.

For blast protocols, this may mean reducing total weekly dosage, dropping the most erythropoietic compound (usually boldenone), or shortening cycle length. The erythropoietic effect is dose-dependent: less androgen, less red cell production.

Therapeutic phlebotomy versus blood donation

Blood donation is widely practiced in the bodybuilding community for haematocrit management, but the evidence for its efficacy is weak. A 2024 review challenged the routine use of phlebotomy for testosterone-induced erythrocytosis, noting that iron depletion from repeated phlebotomy may paradoxically worsen erythropoietic drive through HIF pathway upregulation (Bond et al., 2024).

Practical considerations:

• Many blood services disqualify donors on AAS.
• Standard donation allows one unit (500 mL) every 8-12 weeks; therapeutic phlebotomy programmes may allow more frequent draws.
• Each unit depletes 200-250 mg of iron. Track ferritin at every draw.
• If haematocrit rebounds to pre-phlebotomy levels within 4-6 weeks, phlebotomy alone is not solving the problem.

Evidence-based adjuncts

Hydration: ensures accurate haematocrit readings and reduces haemoconcentration. Aim for at least 3 litres of water daily during heavy training, more in hot environments.

Grapefruit/naringin: a human trial of 36 subjects found that daily grapefruit ingestion over 42 days significantly lowered elevated haematocrit, with the largest reductions in those with the highest baseline values (Robbins et al., 1988). The mechanism involves naringin-induced red cell aggregation with subsequent phagocytic removal. This is a mild adjunct, not a substitute for dose management. The study is small and nearly four decades old.

When to see a haematologist

Seek specialist referral if any of the following apply:

• Haematocrit persistently above 58% despite dose reduction and phlebotomy
• Low serum EPO despite elevated haematocrit (raises suspicion of polycythemia vera)
• NRBCs present on CBC
• Platelet count persistently above 450 x10^9/L (possible myeloproliferative disorder)
• Unexplained haematocrit elevation without clear pharmacological cause
• Symptoms of hyperviscosity: headaches, visual disturbances, numbness, chest tightness

Key takeaways

• The full CBC contains far more clinical information than haemoglobin and haematocrit alone. Red cell indices (MCV, MCH, MCHC, RDW) reveal whether your bone marrow is producing quality red cells or running out of iron.
• Reticulocytes are your bone marrow's live activity meter. A rising reticulocyte count precedes a rising haematocrit by 7-14 days.
• AAS drive erythropoiesis through EPO stimulation, hepcidin suppression, and extended red cell lifespan. Finasteride does not block these effects.
• Boldenone is the most erythropoietic compound per unit of androgenic activity. Testosterone is dose-dependent. Stanozolol's main haematological risk is platelet aggregation, not haematocrit.
• Androgens push neutrophils and monocytes up without changing lymphocytes. The TRAVERSE trial linked this shift directly to venous thromboembolism risk.
• The combined thrombotic risk of high haematocrit, elevated WBC, enhanced platelet reactivity, and dehydration is additive. Hydration is the most modifiable protective factor.
• Phlebotomy is not a long-term solution. It depletes iron, may trigger compensatory EPO surges, and does not address the root cause. Dose reduction comes first.
• If haematocrit exceeds 54% persistently, ask for JAK2 V617F and serum EPO to distinguish AAS-induced secondary polycythemia from polycythemia vera.

---

References

1. Alen, M. (1985). Androgenic steroid effects on liver and red cells. British Journal of Sports Medicine, 19(1), 15-20. PubMed
2. Bachman, E., Feng, R., Travison, T., et al. (2010). Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. Journal of Clinical Endocrinology & Metabolism, 95(10), 4743-4747. PubMed
3. Bachman, E., Travison, T. G., Basaria, S., et al. (2014). Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. Journals of Gerontology: Series A, 69(6), 725-735. PubMed
4. Beggs, L. A., Yarrow, J. F., Conover, C. F., et al. (2014). Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone. American Journal of Physiology: Endocrinology and Metabolism, 307(5), E456-E461. PubMed
5. Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2018). Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744. PubMed
6. Bond, P., Verdegaal, T., & Smit, D. L. (2024). Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocrine Connections, 13(10), e240283. PubMed
7. Camilleri, E., Smit, D. L., van Rein, N., et al. (2023). Coagulation profiles during and after anabolic androgenic steroid use: data from the HAARLEM study. Research and Practice in Thrombosis and Haemostasis, 7(7), 102215. PubMed
8. Chin-Yee, B., Lazo-Langner, A., Butler-Foster, T., Hsia, C., & Chin-Yee, I. (2017). Blood donation and testosterone replacement therapy. Transfusion, 57(3), 578-581. PubMed
9. Christ, E. R., Cummings, M. H., Westwood, N. B., et al. (1997). The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. Journal of Clinical Endocrinology & Metabolism, 82(9), 2985-2990. PubMed
10. Coviello, A. D., Kaplan, B., Lakshman, K. M., et al. (2008). Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology & Metabolism, 93(3), 914-919. PubMed
11. Ferenchick, G., Schwartz, D., Ball, M., & Schwartz, K. (1992). Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. American Journal of Medical Sciences, 303(2), 78-82. PubMed
12. Gagliano-Juca, T., Pencina, K. M., Guo, W., et al. (2020). Differential effects of testosterone on circulating neutrophils, monocytes, and platelets in men. Andrology, 8(5), 1324-1331. PubMed
13. Gagliano-Juca, T., Pencina, K. M., Shang, Y. V., et al. (2025). Association of testosterone-induced increase in neutrophil and monocyte counts with thromboembolic events: the TRAVERSE trial. American Heart Journal, 288, 77-88. PubMed
14. Gangat, N., Szuber, N., & Tefferi, A. (2023). JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management. American Journal of Hematology, 98(6), 965-981. PubMed
15. Heiland, C. E., Schickel, Y., Lehtihet, M., Borjesson, A., & Ekstrom, L. (2023). Supra-physiological doses of anabolic androgenic steroids impact erythropoietin and blood parameters. Drug Testing and Analysis, 15(6), 599-604. PubMed
16. Inamdar Doddamani, L. S., & Jayamma, Y. (2012). Acceleration of neutrophil precursors' maturation and immunostimulation of CD3+, CD4+ lymphocytes by stanozolol in mice. Journal of Steroid Biochemistry and Molecular Biology, 129(3-5), 172-178. PubMed
17. Kluft, C., Preston, F. E., Malia, R. G., et al. (1984). Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thrombosis and Haemostasis, 51(2), 157-164. PubMed
18. Liu, J., Chin-Yee, B., Ho, J., et al. (2025). Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review. Blood Advances, 9(9), 2108-2118. PubMed
19. Long, N., Bassi, S., Pepito, D., & Akhondi, H. (2019). Gerstmann syndrome complicating polycythemia secondary to anabolic steroid use. BMJ Case Reports, 12(6), e229062. PubMed
20. Lundy, S. D., Parekh, N. V., & Shoskes, D. A. (2020). Obstructive sleep apnea is associated with polycythemia in hypogonadal men on testosterone replacement therapy. Journal of Sexual Medicine, 17(7), 1297-1303. PubMed
21. McMartin, M. C., Savkovic, S., Romano, A., et al. (2024). Testosterone and erythrocyte lifespan. Journal of Clinical Endocrinology & Metabolism, 110(1), 114-122. PubMed
22. Ory, J., Nackeeran, S., Balaji, N. C., Hare, J. M., & Ramasamy, R. (2022). Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy. Journal of Urology, 207(6), 1295-1301. PubMed
23. Pengthina, W., & Saelue, P. (2022). Efficacy of oxymetholone in severe and nonsevere acquired aplastic anemia: a propensity score matching analysis. Journal of Blood Medicine, 13, 753-761. PubMed
24. Pikora, K., Kretowska-Grunwald, A., Krawczuk-Rybak, M., & Sawicka-Zukowska, M. (2023). Diagnostic value and prognostic significance of nucleated red blood cells (NRBCs) in selected medical conditions. Cells, 12(14), 1817. PubMed
25. Rha, M-S., Jeong, Y., Kim, J., et al. (2022). Is obstructive sleep apnea associated with erythrocytosis? A systematic review and meta-analysis. Laryngoscope Investigative Otolaryngology, 7(2), 627-635. PubMed
26. Robbins, R. C., Martin, F. G., & Roe, J. M. (1988). Ingestion of grapefruit lowers elevated hematocrits in human subjects. International Journal of Vitamin and Nutrition Research, 58(4), 414-417. PubMed
27. Rosca, A. E., Vladareanu, A. M., Mititelu, A., et al. (2021). Effects of exogenous androgens on platelet activity and their thrombogenic potential in supraphysiological administration: a literature review. Journal of Clinical Medicine, 10(1), 147. PubMed
28. Tashi, T. (2022). Hematocrit, white blood cells, and thrombotic events in the veteran population with polycythemia vera. Federal Practitioner, 39(Suppl 2), S43-S46. PubMed
29. Wang, C., Ning, Z., Lu, Q., et al. (2025). Reference interval establishment for neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index in athletes. Journal of Clinical Laboratory Analysis, 39(5), e70005. PubMed